ScienceBeta

Menu

Benefits Of CBASP For Chronic Depression Fade After 2 Years

disease awareness

The benefits of a specific psychotherapeutic approach may disappear after two years from the conclusion of the psychotherapy, a new study indicates.

Evidence on the long-term efficacy of psychotherapeutic approaches for chronic depression is scarce. The goal of the trial was to evaluate the effects of the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) compared to Supportive Psychotherapy (SP) 1 year and 2 years after treatment termination.

This study presents the results of the 1- and 2-year follow-up assessments of a prospective, multicenter, evaluator-blinded, randomized clinical trial of outpatients with early-onset chronic major depression (n = 268).

Maintenance Treatment

The initial treatment included 32 sessions of CBASP or SP over 48 weeks.

The primary outcome was the rate of “well weeks” (Longitudinal Interval Follow-Up Evaluation; no/minimal symptoms) after 1 year and 2 years. The secondary outcomes were, among others, clinician- and self-rated depressive symptoms, response/remission rates, and quality of life.

Of the 268 randomized patients, 207 (77%) participated in the follow-up. In the intention-to-treat analysis, there was no statistically significant difference between CBASP and SP patients in experiencing well weeks and in remission rates in the 2 years after treatment.

Statistically significant effects were found in favor of CBASP 1 year after treatment termination regarding the rate of well weeks, self-rated depressive symptoms, and depression-related quality of life.

CBASP lost its superiority over SP at some point between the first and the second year. This suggests the necessity of maintenance treatment for early-onset chronically depressed patients remitted with CBASP during the acute therapy phase.

Cognitive Behavioral Analysis System Of Psychotherapy

The cognitive behavioral analysis system of psychotherapy (CBASP) is a talking therapy, a synthesis model of interpersonal and cognitive and behavioral therapies developed (and patented) by James P. McCullough Jr [2000, 2006] of Virginia Commonwealth University specifically for the treatment of all varieties of DSM-IV chronic depression. CBASP is often mistakenly labeled a variant of cognitive therapy (CT) or cognitive behavioral therapy (CBT) but it is not.

McCullough writes that chronic depression (i.e., depressive disorder in adults that lasts continuously for two or more years; one year continuously in adolescents), particularly the type beginning during adolescence (early-onset), is essentially a refractory mood disorder arising from traumatic experiences or interpersonal psychological insults delivered by the patient’s significant others (nuclear or extended family).

The chronic depression mood disorder, at the core, is fueled by a generalized fear of others resulting in a lifetime history of interpersonal avoidance. The disorder rarely remits without proper treatment.

Schramm E., Kriston L., Elsaesser M, Fangmeier T, Meister R, Bausch P, Zobel I., Bailer J., Wambach K., Backenstrass M., Klein J.P., Schoepf D., Schnell K., Gumz A., Löwe B., Walter H., Wolf M., Domschke K., Berger M., Hautzinger M., Härter M.
Two-Year Follow-Up after Treatment with the Cognitive Behavioral Analysis System of Psychotherapy versus Supportive Psychotherapy for Early-Onset Chronic Depression
Psychother Psychosom 2019;88:154–164 https://doi.org/10.1159/000500189

McCullough Jr., James P.
Treatment for Chronic Depression: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
The Guilford Press; August 27, 2003 ISBN: 978-1572309654